REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design

被引：0

作者：

Ghorani, Ehsan ^{[1
]}

Quartagno, Matteo ^{[2
]}

Blackhall, Fiona ^{[3
]}

O'Brien, Mary ^{[4
]}

Ottensmeier, Christian ^{[5
,6
]}

Pizzo, Elena ^{[7
]}

Spicer, James ^{[8
]}

Gilbert, Duncan ^{[2
]}

Baker, Alex ^{[9
]}

Badman, Philip ^{[9
]}

Milner-Watts, Charlotte ^{[4
]}

d'Arienzo, D. Paolo

Dangoor, Adam ^{[10
]}

Adhikaree, Jason ^{[11
]}

Evans, Joanne ^{[12
]}

Leite, Pollyanna ^{[12
]}

Keni, Manjusha ^{[13
]}

Steele, Nicola ^{[14
,15
]}

Gomes, Fabio ^{[3
]}

Gomez-Randulfe, Igor ^{[3
]}

Belitei, Petru ^{[16
]}

Stewart, Grant ^{[17
]}

Barrie, Colin ^{[18
]}

Geldart, Tom ^{[19
]}

Jain, Pooja ^{[20
]}

Justin, Liu K. H. ^{[20
]}

Zubairi, Ishtaiq ^{[14
]}

Muthukumar, Dakshinamoorthy ^{[21
]}

Gray, Lucy ^{[21
]}

Treece, Sarah ^{[22
]}

Aleksic, Aleksandar ^{[23
,24
]}

Tsaknis, Georgios ^{[24
]}

Rathbone, Emma ^{[25
]}

Shaw, Paul ^{[26
]}

Tarver, Kathryn ^{[27
]}

Mahesh, K. B. ^{[2
]}

Seckl, Michael J. ^{[1
]}

机构：

[1] Imperial Coll London, Charing Cross Hosp, Dept Med Oncol, London, England

[2] UCL, Inst Clin Trials & Methodol, MRC Clin Trials Inst, London, England

[3] Christie NHS Fdn Trust, Manchester, England

[4] Royal Marsden NHS Fdn Trust, Sutton, England

[5] Clatterbridge Canc Ctr NHS Fdn Trust, Liverpool, England

[6] Univ Liverpool, Inst Syst Mol & Integrat Biol, Liverpool, England

[7] UCL, Dept Appl Hlth Res, London, England

[8] Kings Coll London, Guys Hosp, London, England

[9] Imperial Coll London, Dept Surg & Canc, Imperial Clin Trials Unit Canc, London, England

[10] Univ Hosp Bristol NHS Fdn Trust, Bristol, England

[11] Nottingham Univ Hosp NHS Trust, Nottingham, England

[12] Imperial Coll Healthcare NHS Trust, London, England

[13] Univ Hosp Derby & Burton NHS Fdn Trust, Derby, England

[14] NHS Greater Glasgowand Clyde, Glasgow, Scotland

[15] NHS Forth Valley, Larbert, Scotland

[16] Royal Devon Univ Healthcare NHS Fdn Trust, Exeter, England

[17] Royal Cornwall Hosp NHS Trust, Truro, England

[18] NHS Lothian, Edinburgh, Scotland

[19] Univ Hosp Dorset NHS Fdn Trust, Bournemouth, England

[20] Leeds Teaching Hosp NHS Trust, Leeds, England

[21] East Suffolk & North Essex NHS Fdn Trust, Colchester, England

[22] North West Anglia NHS Fdn Trust, Peterborough, England

[23] Northampton Gen Hosp NHS Trust, Northampton, England

[24] Kettering Gen Hosp NHS Fdn Trust, Kettering, England

[25] Calderdale & Huddersfield NHS Fdn Trust, Huddersfield, England

[26] Velindre Univ NHS Trust, Cardiff, Wales

[27] Barking Havering & Redbridge Univ Hosp NHS Trust, London, England

来源：

LUNG CANCER | 2024年 / 190卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

204

引用

页数：1

共 50 条

[1] REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm design
Ghorani, Ehsan
Quartagno, Matteo
Blackhall, Fiona
O'Brien, Mary
Ottensmeier, Christian
Pizzo, Elena
Spicer, James
Gilbert, Duncan
Baker, Alex
Badman, Philip
Milner-Watts, Charlotte
d'Arienzo, Paolo D.
Dangoor, Adam
Adhikaree, Jason
Evans, Joanne
Leite, Pollyanna
Keni, Manjusha
Steele, Nicola
Gomes, Fabio
Gomez-Randulfe, Igor
Belitei, Petru
Stewart, Grant
Barrie, Colin
Geldart, Tom
Jain, Pooja
Liu, Justin K. H.
Zubairi, Ishtaiq
Muthukumar, Dakshinamoorthy
Gray, Lucy
Treece, Sarah
Aleksic, Aleksandar
Tsaknis, Georgios
Rathbone, Emma
Shaw, Paul
Tarver, Kathryn
Parmar, Mahesh K. B.
Seckl, Michael J.
LUNG CANCER, 2024, 190 : 108 - 108
[2] REFINE-Lung is a multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design
Ghorani, E.
Quartagno, M.
Blackhall, F.
Gilbert, D. C.
O'Brien, M. E. R.
Ottensmeier, C. H. H.
Pizzo, E.
Spicer, J.
Williams, A.
Badman, P.
Milner-Watts, C.
Parmar, M. K.
Seckl, M. J.
ANNALS OF ONCOLOGY, 2023, 34
[3] REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.
Seckl, Michael
Ghorani, Ehsan
Quartagno, Matteo
Blackhall, Fiona Helen
Gilbert, Duncan C.
O'Brien, Mary E. R.
Ottensmeier, Christian H. H.
Pizzo, Elena
Spicer, James F.
Williams, Alex
Badman, Philip David
Parmar, Mahesh K. B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Outcome predictors for pembrolizumab alone or with chemotherapy in advanced non-small cell lung cancer (NSCLC)
Zullo, L.
Cella, E.
Paoloni, F.
Gualtieri, M.
Barletta, G.
Favero, D.
Parisi, F.
Dellepiane, C.
Rossi, G.
Bennicelli, E.
Zinoli, L.
Cantini, L.
Pecci, F.
Del Mastro, L.
Berardi, R.
Genova, C.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S78 - S79
[5] A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
Theriau, Christopher F.
Feng, Jamie
Eng, Lawson
Shepherd, Frances A.
DeCarolis, Mary
Glenns, Vivian
Kulkarni, Swati
VanderMeer, Rachel
Zurawska-Fortin, Urszula
Hao, Desiree
Le, Lisa
Wozniczka, Isabel
Al-Kindy, Aida
Xie, Danny
Zhang, Tong
Subramanian, Vasanth
Stockley, Tracy
Bradbury, Penelope A.
Liu, Geoffrey
Leighl, Natasha B.
CANCER RESEARCH, 2023, 83 (08)
[6] Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study
Ulmeanu, Ruxandra
Antohe, Ileana
Anisie, Ecaterina
Antoniu, Sabina
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (02) : 165 - 167
[7] Phase 2 study of bortezomib±docetaxel in advanced non-small cell lung cancer (NSCLC)
Fanucchi, M
Fossella, F
Fidias, P
Natale, R
Belt, R
Govindan, R
Raez, L
Schiller, J
Kashala, O
Kelly, K
LUNG CANCER, 2005, 49 : S30 - S30
[8] Phase II study of oxaliplatin and paclitaxel in advanced non-small cell lung cancer (NSCLC).
Mauer, AM
Otterson, G
Rudin, CM
Villalona, M
Ansari, RH
Szeto, L
Vokes, EE
CLINICAL CANCER RESEARCH, 2000, 6 : 4576S - 4576S
[9] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
Lazaro, M
Jorge, M
Castellanos, J
ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
[10] Continuous infusion vinorelbine (VRL) for advanced non-small cell lung cancer (NSCLC). A phase I/III study
Carbantes, F
Benavides, M
Cobo, M
Hebrero, ML
Trujillo, R
Gomez, D
Breton, JJ
de la Gandara, I
Paredes, G
Juarez, C
ANNALS OF ONCOLOGY, 1998, 9 : 97 - 97

← 1 2 3 4 5 →